BPIQ-II, IUPAC name 8-[(3-Bromophenyl)amino]-1H-imidazo[4,5-γ]-quinazoline, is a small molecule chemical inhibitor of the epidermal growth factor receptor (EGFR), and presumably mediates inhibition of endogenous biological pathways for inhibition of axonal regeneration that are mediated through membraneous myelin and chondroitin sulfate proteoglycans. It was discovered in 1996 by Rewcastle et al. at the University of Auckland School of Medicine in New Zealand and Parke-Davis Pharmaceutical Research in Michigan.